Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Acuity Pharmaceuticals, Alnylam, Exiqon, IDT, ERCC

Acuity Pharmaceuticals, Alnylam, Exiqon, IDT, ERCC

Feb 02, 2006
Premium

Acuity Completes Enrollment in Phase II AMD Trial;
Begins Pilot Phase II Study in Diabetic Macular Edema

Acuity Pharmaceuticals said this week that it has completed patient enrollment in a phase II trial of its siRNA-based treatment for age-related macular degeneration. The company also said that it has begun testing the drug, called Cand5, in a pilot phase II study for diabetic macular edema.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

To Keep Up

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

On the Rise in the City

The New York Times reports that a new viral variant of concern has been identified in New York City.

Nature Studies Present Single-Cell Map of Cell Cycle, Approach Identifies Cancer Treatment Resistance Pathways, More

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

What's Popular?

In Gene Silencing/Gene Editing

  1. ERS Genomics Licenses CRISPR Patents to Korean Biotech Firm G+FLAS Life Sciences

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.